The value of pre-season screening for injury prediction: The development and internal validation of a multivariable prognostic model to predict indirect muscle injury risk in elite football (soccer) players.

Tom Hughes, MSc,1 2
Professor Richard D. Riley, PhD,3
Professor Michael J. Callaghan, PhD,*1,2,5
Dr. Jamie C. Sergeant, PhD,* 2 4

1 Manchester United Football Club, AON Training Complex, Birch Road, Off Isherwood Road, Carrington, Manchester. UK.

2 Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

3 Centre for Prognosis Research, School of Primary, Community and Social Care, Keele University, Staffordshire, UK.

4 Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

5 Department of Health Professions, Manchester Metropolitan University, Brooks Building, Bonsall Street, Manchester. UK.

*JCS and MJC contributed equally and are joint last authors

Corresponding author: Tom Hughes

Email: tom.hughes.physio@manutd.co.uk
Twitter:@dt_hughes
ORCID ID: orcid.org/0000-0003-2266-6615

Correspondence address: Manchester United Football Club, AON Training Complex, Birch Road, Off Isherwood Road, Carrington, Manchester. UK. M31 4BH.
Tel: 0161 868 8754
ABSTRACT

Background: In elite football (soccer), periodic health examination (PHE) could provide prognostic factors to predict injury risk.

Objective: To develop and internally validate a prognostic model to predict individualised indirect (non-contact) muscle injury (IMI) risk during a season in elite footballers, only using PHE-derived candidate prognostic factors.

Methods: Routinely collected preseason PHE and injury data were used from 152 players over 5 seasons (1st July 2013 to 19th May 2018). Ten candidate prognostic factors (12 parameters) were included in model development. Multiple imputation was used to handle missing values. The outcome was any time-loss, index indirect muscle injury (I-IMI) affecting the lower extremity. A full logistic regression model was fitted, and a parsimonious model developed using backward-selection to remove factors that exceeded a threshold that was equivalent to Akaike’s Information Criterion (alpha 0.157). Predictive performance was assessed through calibration, discrimination and decision-curve analysis, averaged across all imputed datasets. The model was internally validated using bootstrapping and adjusted for overfitting.

Results: During 317 participant-seasons, 138 I-IMIs were recorded. The parsimonious model included only age and frequency of previous IMIs; apparent calibration was perfect but discrimination was modest (C-index = 0.641, 95% confidence interval (CI) = 0.580 to 0.703), with clinical utility evident between risk thresholds of 37-71%. After validation and overfitting adjustment, performance deteriorated (C-index = 0.589 (95% CI = 0.528 to 0.651); calibration-in-the-large = -0.009 (95% CI = -0.239 to 0.239); calibration slope =0.718 (95% CI= 0.275 to 1.161).

Conclusion: The selected PHE data were insufficient prognostic factors from which to develop a useful model for predicting IMI risk in elite footballers. Further research should prioritise identifying novel prognostic factors to improve future risk prediction models in this field.

Trial registration number = NCT03782389

Keywords: Athlete, Athletic Injury, Injury prevention, Risk, Sport, Sprains and strains.
KEY POINTS

- Factors measured through preseason screening generally have weak prognostic strength for future indirect muscle injuries and further research is needed to identify novel, robust prognostic factors.

- Because of sample size restrictions and until the evidence base improves, it is likely that any further attempts at creating a prognostic model at individual club level would also suffer from poor performance.

- The value of using preseason screening data to make injury predictions or to select bespoke injury prevention strategies remains to be demonstrated, so screening should only be considered as useful for detection of salient pathology or for rehabilitation/performance monitoring purposes at this time.
BACKGROUND

In elite football (soccer), indirect (non-contact) muscle injuries (IMIs) predominantly affect the lower extremities and account for 30.3% to 47.9% of all injuries that result in time lost to training or competition [1-5]. Reduced player availability negatively impacts upon medical [6] and financial resources [7, 8], and has implications for team performance [9]. Therefore, injury prevention strategies are important to professional teams [9].

Periodic health examination (PHE), or screening, is a key component of injury prevention practice in elite sport [10]. Specifically, in elite football, PHE is used by 94% of teams and consists of medical, musculoskeletal, functional and performance tests that are typically evaluated during preseason and in-season periods [11]. PHE has a rehabilitation and performance monitoring function [12] and is also used to detect musculoskeletal or medical conditions that may be dangerous or performance limiting [13]. Another perceived role of PHE is to recognise and manage factors that may increase, or predict, an athlete’s future injury risk [10], although this function is currently unsubstantiated [13].

PHE-derived variables associated with particular injury outcomes (such as IMIs) are called prognostic factors [14], which can be used to identify risk differences between players within a team [12]. Single prognostic factors are unlikely to satisfactorily predict an individual’s injury risk if used independently [15]. However, several factors could be combined in a multivariable prognostic prediction model to offer more accurate personalised risk estimates for the occurrence of a future event or injury [15, 16]. Such models could be used to identify high-risk individuals who may require an intervention that is designed to reduce risk [17], thus assisting decisions in clinical practice [18]. Despite the potential benefits of prognostic
models for injury, we are unaware of any that have been developed using PHE data in elite football [19].

Therefore, the aim of this study was to develop and internally validate a prognostic model to predict individualised IMI risk during a season in elite footballers, using a set of candidate prognostic factors derived from preseason PHE data.

**METHODS**

The methods have been described in a published protocol [20] so will only be briefly outlined. This study has been registered on ClinicalTrials.gov (identifier: NCT03782389) and is reported according to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) statement [21, 22].

**Data Sources**

This study was a retrospective cohort design. Eligible participants were identified from a population of male elite footballers, aged 16-40 years old at Manchester United Football Club. A dataset was created using routinely collected injury and preseason PHE data over 5 seasons (1st July 2013 to 19th May 2018). For each season, which started on 1st July, participants completed a mandatory PHE during week 1 and were followed up to the final first team game of the season. If eligible participants were injured at the time of PHE, a risk assessment was completed by medical staff. Only tests that were appropriate and safe for the participant’s condition were completed; examiners were not blinded to injury status.
Participants and eligibility criteria
During any season, participants were eligible if they: 1) were not a goalkeeper; and 2) participated in PHE for the relevant season. Participants were excluded if they were not contracted to the club for the forthcoming season at the time of PHE.

Ethics and Data Use
Informed consent was not required as data were captured from the mandatory PHE completed through the participants’ employment. The data usage was approved by the Club and University of Manchester Research Ethics Service.

Outcome
The outcome was any time-loss, index IMI (I-IMI) of the lower extremity. That is, any I-IMI sustained by a participant during matches or training, which affected lower abdominal, hip, thigh, calf or foot muscle groups and prohibited future football participation [23]. I-IMIs were graded by a club doctor or physiotherapist according to the validated Munich Consensus Statement for the Classification of Muscle Injuries in Sport [24, 25], during routine assessments undertaken within 24h of injury. These healthcare professionals were not blinded to PHE data.

Sample size
We allowed a maximum of one candidate prognostic factor parameter per 10 I-IMIs, which at the time of protocol development, was the main recommendation to minimise overfitting (Additional file 1) [20, 26]. The whole dataset was used for model development and internal validation, which agrees with methodological recommendations [27].
Candidate Prognostic Factors

The available dataset contained 60 candidate factors [20]. Because of the sample size considerations, before any analysis, the set of candidate factors was reduced. Initially, an audit was conducted to quantify missing values and to determine the measurement reliability of the eligible candidate factors [20]. Any candidate factors which had greater than 15% missing data, or where reliability was classed as fair to poor (intraclass correlation coefficient <0.70) were excluded [20] (Additional file 2). Of the remaining 45 eligible factors, previous evidence of prognostic value [19] and clinical reasoning were used to select candidate prognostic factors suitable for inclusion [20]. This process left a final set of 10 candidate factors, represented by 12 model parameters (Table 1). The 35 factors that were not included in model development are also listed in Additional File 2, and will be utilised in a related, forthcoming exploratory study which aims to examine their association with indirect muscle injuries in elite football players.
Table 1: Set of candidate prognostic factors (with corresponding number of parameters) for model development.

| Selection method                  | Candidate Prognostic factor                                      | Measurement unit                        | Number of model parameters corresponding to PF | Measurement method | Data type | Reliability (if applicable) |
|-----------------------------------|------------------------------------------------------------------|-----------------------------------------|-----------------------------------------------|--------------------|-----------|-----------------------------|
| Systematic review/clinical reasoning | Age                                                              | Years & days                            | 1                                             | Date of birth      | Continuous | N/A                         |
|                                    | Frequency of previous muscle injuries within 3 years prior to PHE | Count                                   | 1                                             | Medical records    | Discrete | N/A                         |
|                                    | Most recent previous muscle injury within 3 years prior to baseline PHE | Never (ref); < 6 months; 6-12 months; > 12 months | 3                                             | Medical records    | Categorical | N/A                         |
| Data quality/clinical reasoning    | CMJ peak power                                                    | Watts                                   | 1                                             | CMJ using force plates | Continuous | Text-retest ICC = 0.92-0.98 [28] |
|                                    | PROM hip joint internal rotation difference*                      | Degrees                                 | 1                                             | Supine ROM test using digital inclinometer | Continuous | Intra-rater ICC= 0.90 [29]  |
|                                    | PROM hip joint external rotation difference*                      | Degrees                                 | 1                                             | Supine ROM test using digital inclinometer | Continuous | Intra-rater ICC= 0.90 [29]  |
|                                    | Hip flexor muscle length difference*                              | Degrees                                 | 1                                             | Thomas test using digital inclinometer         | Continuous | Inter-rater ICC = 0.89 [30]  |
|                                    | Hamstring muscle length/neural mobility difference*               | Degrees                                 | 1                                             | SLR using digital inclinometer                  | Continuous | Intra-rater ICC = 0.95-0.98 [31] |
|                                    | Calf muscle length difference*                                     | Degrees                                 | 1                                             | WBL using digital inclinometer                  | Continuous | Inter-rater ICC = 0.80- 0.95 [33, 34] |
|                                    | BMI                                                              | Kg/m²                                    | 1                                             | Composite height (cm) and weight (kg)           | Continuous | -                           |

Key: PF= prognostic factor; PHE= periodic health examination; ref= reference category (does not count as a model parameter); WBL= weight bearing lunge; CMJ= countermovement jump; ROM= range of movement; PROM= passive range of movement; ICC= intraclass correlation coefficient; SLR= straight leg raise; BMI= body mass index; Kg= kilos; m= mass; Note: * denotes between limb differences.

Statistical analysis

Data handling – outcome measures

Each participant-season was treated as independent. Participants who sustained an an I-IMI were no longer considered at risk for that season and were included for further analysis at the start of the next season if still eligible. Any upper limb IMI, trunk IMI or non-IMI injuries were ignored and participants were still considered at risk.

Eligible participants who were loaned to another club throughout that season, but had not sustained an I-IMI prior to the loan, were still considered at risk. I-IMIs that occurred whilst on loan were included for analysis, as above. Permanently transferred participants (who had
not sustained an I-IMI prior to leaving), were recorded as not having an I-IMI during the relevant season and exited the cohort at the season end.

**Data handling – missing data**

Missing values were assumed to be missing at random [20]. The continuous parameters generally demonstrated non-normal distributions, so were transformed using normal scores [35] to approximate normality before imputation, and back-transformed following imputation [36]. Multivariate normal multiple imputation was performed, using a model that included all candidates and I-IMI outcomes. Fifty imputed datasets were created in Stata 15.1 (StataCorp LLC, Texas, USA) and analysed using the ‘mim’ module.

**Prognostic model development**

Continuous parameters were retained on their original scales and their effects assumed linear [22]. A full multivariable logistic regression model was constructed, which contained all 12 parameters. Parameter estimates and results were combined across imputed datasets using Rubin’s Rules [37]. To develop a parsimonious model that would be easier to utilise in practice, backward variable selection was performed using estimates pooled across the imputed datasets at each stage of the selection procedure to successively remove non-significant factors with p-values > 0.157. This threshold was selected to approximate equivalence with Akaike’s Information Criterion [38, 39]. Multiple parameters representing the same candidate factor were tested together so that the whole factor was either retained or removed. Candidate interactions were not examined and no terms were forced into the model. All analyses were conducted in Stata 15.1.
Assessment of model performance

The full and parsimonious models were used to predict I-IMI risk over a season, for every participant-season in all imputed datasets. For all performance measures, each model’s apparent performance was assessed in each imputed dataset and then averaged across all imputed datasets using Rubin’s Rules [37]. Discrimination determines a model’s ability to differentiate between participants who have experienced an outcome compared to those who have not [40], quantified using the concordance index (c-index). This is equivalent to the area under the receiver operating characteristic (ROC) curve for logistic regression, where 1 demonstrates perfect discrimination, while 0.5 indicates that discrimination is no better than chance [41].

Calibration determines the agreement between the model’s predicted outcome risks and those observed [42], evaluated using an apparent calibration plot in each imputed dataset. All predicted risks were divided into ten groups defined by tenths of predicted risk. The mean predicted risks for the groups were plotted against the observed group outcome proportions with corresponding 95% confidence intervals (CIs). A loess smoothing algorithm showed calibration across the range of predicted values [43]. For grouped and smoothed data points, perfect predictions lie on the 45° line (i.e. a slope of 1).

The systematic (mean) error in model predictions was quantified using calibration-in-the-large (CITL), which has an ideal value of 0 [40, 42], and the expected/observed (E/O) statistic, which is the ratio of the mean predicted risk against the mean observed risk (ideal value of 1) [40, 42]. The degree of over or underfitting was determined using the calibration slope, where a value of 1 equals perfect calibration on average across the entire range of predicted risks [22]. Nagelkerke’s pseudo-R² was also calculated, which quantifies the
overall model fit, with a range of 0 (no variation explained) to 1 (all variation explained) [44].

Assessment of clinical utility

Decision-curve analysis was used to assess the parsimonious model’s apparent clinical usefulness in terms of net benefit (NB) if used to allocate possible preventative interventions. This assumed that the model’s predicted risks were classed as positive (i.e. may require a preventative intervention) if greater than a chosen risk threshold, and negative otherwise. NB is then the difference between the proportion of true positives and false positives, where both were weighted by the odds of the chosen risk threshold and also divided by the sample size [45]. Positive NB values suggest the model is beneficial compared to treating none, which has no benefit to the team but with no negative cost and efficiency implications. The maximum possible NB value is the proportion with the outcome in the dataset.

The model’s NB was also compared to the NB of delivering an intervention to all individuals. This is considered a treat-all strategy, offering maximum benefit to the team, but with maximum negative cost and efficiency implications [17]. A model has potential clinical value if it demonstrates higher NB than the default strategies over the range of risk thresholds which could be considered as high risk in practice [46].

Internal validation and adjustment for overfitting

To examine overfitting, the parsimonious model was internally validated using 200 bootstrap samples, drawn from the original dataset. In each sample, the complete model-building procedure (including multiple imputation, backward variable selection and performance
assessment) was conducted as described earlier. The difference in apparent performance (of a bootstrap model in its bootstrap sample) and test performance (of the bootstrap model in the original dataset) was averaged across all samples. This generated optimism estimates for the calibration slope, CITL and C-index statistics. These were subtracted from the original apparent calibration slope, CITL and C-index statistics to obtain final optimism-adjusted performance estimates. The Nagelkerke $R^2$ was adjusted using a relative reduction equivalent to the relative reduction in the calibration slope.

To produce a final model adjusted for overfitting, the regression coefficients produced in the parsimonious model were multiplied by the optimism-adjusted calibration slope (also termed a uniform shrinkage factor), to adjust (or shrink) for overfitting [47]. Finally, the CITL (also termed model intercept) was then re-estimated to give the final model, suitable for evaluation in other populations or datasets.

**Complete case and sensitivity analyses**

To determine the effect of multiple imputation and player transfer assumptions on model stability, the model development process was repeated: 1) as a complete case analysis; and 2) as sensitivity analyses which excluded all participant-seasons where participants had not experienced an I-IMI up to the point of loan or transfer, which were performed as both multiple imputation and complete case analyses.
RESULTS

Participants

During the five seasons, 134 participants were included, contributing 317 participant-seasons and 138 IMIs in the primary analyses (Fig. 1). Three players were classified as injured when they took part in PHE (which affected three participant-seasons). This meant they were unavailable for full training or to play matches at that time. However, these players had commenced football specific, field-based rehabilitation around this time, so also had similar exposure to training activities as the uninjured players. As such, these players were included in the cohort because it was reasonable to assume that they could also be considered at risk of an I-IMI event even during their rehabilitation activities.

Table 2 describes the frequency of included participant-seasons, and the frequency and proportion of recorded I-IMI outcomes across all five seasons. For the sensitivity analyses (excluding loans and transfers), 260 independent participant-seasons with 129 IMIs were included; 36 participants were transferred on loan, while 14 participants were permanently transferred during a season, which excluded 57 participant-seasons in total (Fig. 1). Table 2 also describes the frequency of excluded participant-seasons where players were transferred either permanently or on loan, across the 5 seasons.
Fig. 1 Participant flow chart

Number of players who underwent PHE (1st July 2013 – 19th May 2018)

n = 152

Number of participants who were not eligible (with reasons for exclusion):
Goalkeepers: 18

PRIMARY ANALYSIS
134 Included players, where:
45 Players participated in 1 season
34 Players participated in 2 seasons
25 Players participated in 3 seasons
21 Players participated in 4 seasons
9 Players participated in 5 seasons
= 317 participant-seasons

29 Players loaned in 1 season = 29 participant-seasons excluded
7 Players loaned in 2 seasons = 14 participant-seasons excluded
14 Players transferred permanently (2 in July, 7 in August, 5 in January) = 14 participant-seasons excluded
Total = 57 participant-seasons excluded

SENSITIVITY ANALYSIS
= 260 participant-seasons

Main analysis (using multiple imputation)
317 participant-seasons (138 I-IMI events/179 non-events)

Complete case analysis
265 participant-seasons (115 I-IMI events/150 non-events)

Main sensitivity analysis (using multiple imputation)
260 participant-seasons (129 I-IMI events/131 non-events)

Complete case sensitivity analysis
217 participant-seasons (106 I-IMI events/111 non-events)

Key: n=participants; I-IMI=index indirect muscle injury
Table 2 Frequency of included participant-seasons, I-IMI outcomes and participant-seasons affected by transfers, per season (primary analysis).

| Season | Included participant-seasons | Participant-seasons with an I-IMI outcome (%) | Participant-seasons where players transferred on loan | Participant-seasons where players transferred permanently |
|--------|------------------------------|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| 1 (2013/2014) | 58 | 26 (44.83) | 16 | 1 |
| 2 (2014/2015) | 66 | 21 (31.82) | 10 | 4 |
| 3 (2015/2016) | 66 | 29 (43.93) | 7 | 5 |
| 4 (2016/2017) | 61 | 28 (45.90) | 4 | 3 |
| 5 (2017/2018) | 66 | 34 (51.52) | 6 | 1 |
| Total | 317 | 138 (44.00) | 43 | 14 |

Key: I-IMI = index indirect muscle injury

Table 3 shows anthropometric and all prognostic factor characteristics for participants included in the primary analyses. These were similar to those included in the sensitivity analyses (Additional file 3).

Table 3 Characteristics of included participants in the primary analysis

| Characteristic/candidate prognostic factors | Measurement method | Data type | Frq. (%) if categorical | Min | Lower quartile | Median | Upper quartile | Max | Missing values n (%) |
|--------------------------------------------|--------------------|-----------|-------------------------|-----|----------------|--------|---------------|-----|---------------------|
| **Anthropometrics**                         |                    |           |                         |     |                |        |               |     |                     |
| Age at PHE (years)                         | Birthdate          | Cont.     | 16.01                   | 17.80| 19.69          | 23.56  | 39.59         | 0   | (0)                |
| Height (cm)                                | Standing height    | Cont.     | 164.3                   | 176.0| 180.0          | 185.5  | 195.0         | 18  | (5.68)             |
| Weight (kg)                                | Digital scales     | Cont.     | 56.8                    | 69.2 | 73.6           | 80.0   | 94.0          | 18  | (5.68)             |
| BMI (Kg/m²)                                | Calculated using the formula: Kg/m² | Cont. | 18.1                    | 21.8 | 22.7           | 23.7   | 29.1          | 23  | (7.26)             |
| **Past medical history**                   |                    |           |                         |     |                |        |               |     |                     |
| Freq. of previous IMIs in 3 years prior to PHE | Medical records | Dis./cont. | 0 | 0 | 1 | 2 | 7 | 0 | (0)            |
| Most recent previous IMI in 3 years prior to PHE |                   |           |                         |     |                |        |               |     |                     |
| Never                                     | Medical records    | Cat.     | 143 (45.11)             | -   | -              | -      | -             | -   | 0 (0)              |
| <6 months                                 | Medical records    | Cat.     | 48 (15.14)              | -   | -              | -      | -             | -   | 0 (0)              |
| 6-12 months                               | Medical records    | Cat.     | 52 (16.40)              | -   | -              | -      | -             | -   | 0 (0)              |
| >12 months                                | Medical records    | Cat.     | 74 (23.34)              | -   | -              | -      | -             | -   | 0 (0)              |
| **Musculoskeletal Examination**            |                    |           |                         |     |                |        |               |     |                     |
| PROM hip internal rotation difference (deg.) | SUPINE ROM test with digital inclinometer | Cont. | -25.0                   | -3.0 | 0.0            | 5.0    | 20.0          | 20  | (6.31)             |
| PROM hip external rotation difference (deg.) | SUPINE ROM test with digital inclinometer | Cont. | -20.0                   | -5.0 | 0.0            | 5.0    | 25.0          | 20  | (6.31)             |
| Hip flexor length difference (deg.)         | Thomas test with digital inclinometer | Cont. | -20.0                   | -2.0 | 0.0            | 3.0    | 14.0          | 23  | (7.26)             |
| Hamstring length/neural mobility difference (deg.) | SLR with digital inclinometer | Cont. | -20.0                   | 0.0  | 0.0            | 0.0    | 15.0          | 23  | (7.26)             |
| Calf muscle length difference (deg.)        | WIL with digital inclinometer | Cont. | -20.0                   | -2.0 | 0.0            | 3.0    | 15.0          | 20  | (6.31)             |
| **Lower Extremity Power**                  |                    |           |                         |     |                |        |               |     |                     |
| CMJ power (Watts)                          | CMJ using force platform | Cont. | 2625.0                  | 3707.0| 4150.0         | 4662.0 | 6577.0        | 42  | (13.25)            |
Missing data and multiple imputation

All I-IMI, age and previous muscle injury data were complete (Table 3). For all other candidates, missing data ranged from 6.31% (for hip internal and external rotation difference) to 13.25% for countermovement jump (CMJ) power (Table 3). The distribution of imputed values approximated observed values (Additional file 4), confirming their plausibility.

Model development

Table 4 shows the parameter estimates for the full model and parsimonious model after variable selection (averaged across imputations).
### Table 4: Results of the full and parsimonious multivariable logistic regression models, with prediction formulae

| Candidate prognostic factors | Full model | Parsimonious model (after variable selection) | Final model after adjustment (shrinkage) for overfitting |
|-----------------------------|------------|---------------------------------------------|--------------------------------------------------|
|                             | $\beta$† | 95% CI | OR | 95% CI | $P$ Value | $\beta$† | 95% CI | OR | 95% CI | $P$ Value | Adjusted $\beta$† | Adjusted OR |
| **Anthropometrics**          |           |       |    |       |            |           |       |    |       |            |           |            |            |
| Age at PHE (years)          | 0.095     | 0.032 to 0.159 | 1.100 | 1.032 to 1.172 | 0.003 | 0.091 | 0.034 to 0.148 | 1.095 | 1.035 to 1.159 | 0.002 | 0.065* | 1.068 |
| BMI (Kg/m$^2$)              | -0.078   | -0.249 to 0.093 | 0.925 | 0.780 to 1.098 | 0.372 |         |               |       |            |            |
| **Past medical history**    |           |       |    |       |            |           |       |    |       |            |           |            |            |
| Freq. of previous IMIs in 3 years prior to PHE | 0.235 | -0.037 to 0.507 | 1.265 | 0.964 to 1.661 | 0.090 | 0.168 | -0.015 to 0.350 | 1.182 | 0.986 to 1.419 | 0.0 | 0.120* | 1.128 |
| Most recent previous IMI in 3 years prior to PHE |           |       |    |       |            |           |       |    |       |            |           |            |            |
| **Musculoskeletal Examination** |           |       |    |       |            |           |       |    |       |            |           |            |            |
| PROM hip internal rotation difference (deg.) | 0.008 | -0.029 to 0.044 | 1.008 | 0.971 to 1.045 | 0.682 | - | - | - | - | - | - | - | - |
| PROM hip external rotation difference (deg.) | 0.024 | -0.011 to 0.059 | 1.024 | 0.989 to 1.061 | 0.180 | - | - | - | - | - | - | - | - |
| Hip flexor length difference (deg.) | 0.026 | -0.032 to 0.083 | 1.026 | 0.969 to 1.087 | 0.382 | - | - | - | - | - | - | - |
| Hamstring length/nerve mobility difference (deg.) | -0.007 | -0.083 to 0.068 | 0.993 | 0.920 to 1.070 | 0.846 | - | - | - | - | - | - | - |
| Calf muscle length difference (deg.) | 0.018 | -0.033 to 0.069 | 1.018 | 0.967 to 1.072 | 0.493 | - | - | - | - | - | - | - | - |
| **Lower Extremity Power**   |           |       |    |       |            |           |       |    |       |            |           |            |            |
| CMJ power (Watts)            | 0.000   | 0.000 to 0.001 | 1.000 | 1.000 to 1.001 | 0.394 | - | - | - | - | - | - | - | - |
| Intercept                   | -1.448  | -3.564 to 1.668 | - | - | - | - | - | - | - | - | - | - | - |

**Model Performance Statistics**

| Statistics | Apparent performance (95% CI) | Apparent performance (95% CI) – before validation | Optimum- adjusted performance with 95% CI – after validation |
|------------|-------------------------------|--------------------------------------------------|--------------------------------------------------|
| Nagelkerke R$^2$ | 0.120 | 0.089 | 0.064 |
| Calibration slope | 1.000 (0.608 to 1.392) | 1.000 (0.557 to 1.443) | 0.718 (0.275 to 1.161) |
| CITL | 0.000 (-0.233 to 0.233) | 0.000 (-0.230 to 0.230) | -0.009 (-0.239 to 0.239) |
| C-index | 0.670 (0.609 to 0.731) | 0.641 (0.580 to 0.703) | 0.589 (0.528 to 0.651) |

**Key:** $\beta$† = Beta (regression) coefficient; SE= standard error; CI= confidence interval; OR= odds ratio; PHE= periodic health examination; Freq.= frequency; IMI= indirect muscle injury; deg.= degrees; BMI= body mass index; kg/m$^2$ = kilograms/body height squared; ref= reference category; †= $\beta$ values are expressed per one-unit increase for all continuous variables, and according to category for the most recent IMI within 3 years prior to PHE; *Adjusted regression value after multiplication with uniform shrinkage factor of 0.718; ** Re-estimated model intercept after internal validation. Note: Factors in **bold** indicate significance at the 0.157 level (equivalent to Akaike’s information criterion).

**Prediction formula of parsimonious model (used during internal validation procedure):** The predicted probability of a player sustaining an IMI during a season can be calculated using the following formula: Probability = 1/ (1 + exp(2.384 - 0.091 x age – 0.168 x freq. of previous IMIs within 3 years prior to PHE)). If desired, a percentage risk score can be obtained by multiplying the probability $\times$ 100.

**Prediction formula for final model (for use on new datasets):** The predicted probability of a player sustaining an IMI during a season can be calculated using the following formula: Probability = 1/ (1 + exp(1.786 - 0.065 x age – 0.120 x freq. of previous IMIs within 3 years prior to PHE)). Note: exp = exponentiate. If desired, a percentage risk score can be obtained by multiplying the probability $\times$ 100.
For both models, only age and frequency of previous IMIs had a statistically significant (but modest) association with increased I-IMI risk ($p < 0.157$). No clear evidence for an association was observed for any other candidate factor.

**Model performance assessment and clinical utility**

Table 4 shows the apparent performance measures for the full and parsimonious models, all of which were similar. Fig. 2 shows the apparent calibration of the parsimonious model in the dataset used to develop the model (i.e. before adjustment for overfitting). These were identical across all imputed datasets because the retained prognostic factors contained no missing values. The parsimonious model had perfect apparent overall CITL and calibration slope by definition, but calibration was more variable around the 45° degree line between the expected risk ranges of 28% to 54%. Discrimination was similarly modest for the full (C-index = 0.670, 95% CI=0.609 to 0.731) and parsimonious models (C-index = 0.641, 95%CI = 0.580-0.703). The apparent overall model fit was low for both models, indicated by Nagelkerke $R^2$ values of 0.120 for the full model and 0.089 for the parsimonious model.
Fig. 2 Apparent calibration of the parsimonious model (before adjustment for overfitting).

![Summary Statistics Graph]

**Key:** E:O = expected: observed ratio; CI = confidence interval

Fig. 3 displays the decision-curve analysis. The NB of the parsimonious model was comparable to the treat-all strategy at risk thresholds up to 31%, marginally greater between 32% and 36% and exceeded the NB of either default strategies between 37% and 71%.
Internal validation and adjustment for overfitting

Table 4 shows the optimism-adjusted performance statistics for the parsimonious model, with full internal validation results shown in Additional file 9. After adjustment for optimism, the overall model fit and the model’s discrimination performance deteriorated (Nagelkerke $R^2 = 0.064$; c-index = 0.589 (95% CI= 0.528 to 0.651). Furthermore, bootstrapping suggested the model would be severely overfitted in new data (calibration slope = 0.718 (95% CI=0.275 to 1.161)), so a shrinkage factor of 0.718 was applied to the parsimonious parameter estimates and the model intercept re-estimated to produce our final model (Table 4).

Complete case and sensitivity analyses

The full and parsimonious models were robust to complete case analyses and excluding loans and transfers, with comparable apparent performance estimates. For the full models, the c-
index range was 0.675 to 0.705 and Nagelkerke $R^2$ range was 0.135 to 0.178, while for the parsimonious models, the c-index range was 0.632 to 0.691 and Nagelkerke $R^2$ range was 0.102 to 0.154 (Additional files 5-9). The same prognostic factors were selected in all parsimonious models. The degree of estimated overfitting observed in the complete case and sensitivity analyses was comparable to that observed in the main analysis (calibration slope range = 0.678 to 0.715) (Additional files 5-9).

**DISCUSSION**

We have developed and internally validated a multivariable prognostic model to predict individualised I-IMI risk during a season in elite footballers, using routinely, prospectively collected preseason PHE and injury data that was available at Manchester United Football Club. This is the only study that we know of that has developed a prognostic model for this purpose, so the results cannot be compared to previous work.

We included both a full model which did not include variable selection and a parsimonious model, which included a subset of variables that were statistically significant. The full model was included because overfitting is likely to increase when variable inclusion decisions are based upon $p$-values. In addition, the use of $p$-value thresholds for variable selection is somewhat arbitrary. However, the overfitting that could have arisen in the parsimonious model, after using $p$-values in this way was accounted for during the bootstrapping process, which replicated the variable selection strategy based on $p$-values in each bootstrap sample.

The performance of the full and parsimonious models was similar, which means that utilising all candidate factors offered very little advantage over using two for making predictions. Indeed, variable selection eliminated 8 candidate prognostic factors that had no clear
evidence for an association with I-IMIs. Our findings confirm previous suggestions that PHE tests designed to measure modifiable physical and performance characteristics typically offer poor predictive value [10]. This may be because unless particularly strong associations are observed between a PHE test and injury outcome, the overlap in scores between individuals who sustain a future injury and those who do not results in poor discrimination [10]. Additionally, after measurement at a single timepoint (i.e. pre-season), it is likely that the prognostic value of these modifiable factors may vary over time [48] due to training exposure, environmental adaptations and the occurrence of injuries [49].

The variable selection process resulted in a model which included only age and the frequency of previous IMIs within the last three years, which are simple to measure and routinely available in practice. Our findings were similar to the modest association previously observed between age and hamstring IMIs in elite players [19]. However, while a positive previous hamstring IMI history has a confirmed association with future hamstring IMIs [19], we found that for lower extremity I-IMIs, cumulative IMI frequency was preferred to the time proximity of any previous IMI as a multivariable prognostic factor. Nevertheless, the weak prognostic strength of these factors explains the parsimonious model’s poor discrimination and low potential for clinical utility.

Our study is the first to utilise decision-curve analysis to examine the clinical usefulness of a model for identifying players at high risk of IMIs and who may benefit from preventative interventions such as training load management, strength and conditioning or physiotherapy programmes. Our parsimonious model demonstrated no clinical value at risk thresholds of less than 36%, because its NB was comparable to that of providing all players with an intervention. Indeed, the only clinically useful thresholds that would indicate a high-risk
player would be 37-71%, where the model’s NB was greater than giving all players an intervention. However, because of the high baseline IMI risk in our population (approximately 44% of participant-seasons affected), the burden of IMIs [1-5] and the minimal costs [10] versus the potential benefits of such preventative interventions in an elite club setting, these thresholds are likely to be too high to be acceptable in practice. Accordingly, it would be inappropriate to allocate or withhold interventions based upon our model’s predictions.

Because of severe overfitting our parsimonious model was optimistic, which means that if used in new players, prediction performance would likely to be worse [39]. Although our model was adjusted to account for overfitting and hence improve its calibration performance in new datasets, given the limitations in performance and clinical value, we cannot recommend that it is validated externally or used in clinical practice.

This study has some limitations. We acknowledge that the development of our model does not formally take account of the use of existing injury prevention strategies, including those informed by PHE, and their potential effects on the outcome. Rather, we predict I-IMIs under typical training and match exposure, and under routine medical care. In addition, it should be noted that injury risk predictions at an elite level football club may not generalise to other types of football clubs or sporting institutions, where ongoing injury prevention strategies may not be comparable in terms of application and equipment.

We measured candidate factors at one timepoint each season and assumed that participant-seasons were independent. While statistically complex, future studies may improve predictive
performance and external validity by harnessing longitudinal measurements and incorporating between-season correlations.

We did not perform a competing risks analysis to account for players not being exposed to training and match play due to injuries other than I-IMIs. That is, our approach predicted the risk of I-IMIs in the follow up of players, allowing other injury types to occur and therefore possibly limiting the opportunity for I-IMIs during any rehabilitation period. The competing risk of the occurrence of non-IMIs was therefore not explicitly modelled and players remained in the risk set after a non-IMI had occurred.

We also merged all lower extremity I-IMIs rather than using specific muscle group outcomes. Although less clinically meaningful, this was necessary to maximise statistical power. Nevertheless, our limited sample size prohibited examination of complex non-linear associations and permitted a small number of candidates to be considered. A lack of known prognostic factors [19] meant that selection was mainly guided by data quality control processes and clinical reasoning, so it is possible that important factors were not included.

Risk prediction improves when multiple factors with strong prognostic value are used [15]. Therefore, future research should aim to identify novel prognostic factors, so that these can be used to develop models with greater potential clinical benefit. This may also allow updating of our model to improve its performance and clinical utility [50].

Until the evidence base improves, and because of sample size limitations, it is likely that any further attempts to create a prognostic model at individual club level would suffer similar issues. Importantly, this means that for any team, the value of using preseason PHE data to
make individualised predictions or to select bespoke injury prevention strategies remains to be demonstrated. However, the pooling of individual participant data from several participating clubs may increase sample sizes sufficiently to allow further model development studies [51], where a greater number of candidate factors could be utilised.

**CONCLUSION**

Using PHE and injury data available pre-season, we have developed and internally validated a prognostic model to predict I-IMI risk in players at an elite club, using current methodological best practice. The paucity of known prognostic factors and data requirements for model building severely limited the model’s performance and clinical utility, so it cannot be recommended for external validation or use in practice. Further research should prioritise identifying novel prognostic factors to improve future risk prediction models in this field.

**DECLARATIONS**

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

The data usage was approved by Manchester United Football Club and the Research Ethics Service at the University of Manchester. Informed consent was not required as data were captured from the mandatory PHE completed through the participants’ employment.

**CONSENT FOR PUBLICATION**

Not required.

**AVAILABILITY OF DATA AND MATERIALS**

An anonymised summary of the dataset that was analysed during this study may be available from the corresponding author on reasonable request.
COMPETING INTERESTS

Tom Hughes and Michael J. Callaghan are employed by Manchester United Football Club. Richard D. Riley, and Jamie C. Sergeant declare that they have no known conflicts of interest.

FUNDING

The lead researcher (TH) is receiving sponsorship from Manchester United Football Club to complete a postgraduate PhD study programme. This work was also supported by Versus Arthritis: grant number 21755.

AUTHORS’ CONTRIBUTIONS

TH was responsible for the conceptualisation of the project, study design, database construction, data extraction and cleaning, protocol development and protocol writing. TH conducted the data analysis, interpretation and wrote the main manuscript. RR provided statistical guidance and assisted with development of the study design, analysis, and edited manuscript drafts. MC assisted with the study conceptualisation and design, protocol development, clinical interpretation and editing the manuscript drafts. JS provided guidance with the study design, development of the analysis and protocol, supervision and interpretation of the analysis, as well as editing the study manuscripts. All authors read and approved this final manuscript.

ACKNOWLEDGEMENTS

The authors would like to thank all staff within the Medical and Sports Science Department at Manchester United for their continuing help and support with this manuscript and thank all
players for their participation (without whom this study would not be possible). The authors also thank the Centre for Epidemiology Versus Arthritis for their support: Versus Arthritis grant number 21755.

REFERENCES

1. Ekstrand J, Hagglund M, Walden M. Epidemiology of muscle injuries in professional football (soccer). Am J Sports Med. 2011;39(6):1226-32.

2. Falese L, Della Valle P, Federico B. Epidemiology of football (soccer) injuries in the 2012/2013 and 2013/2014 seasons of the Italian Serie A. Res Sports Med. 2016;24(4):426-32.

3. Larruskain J, Lekue JA, Diaz N, Ondrioza A, Gil SM. A comparison of injuries in elite male and female football players: A five-season prospective study. Scand J Med Sci Sports. 2018;28(1):237-45.

4. Leventer L, Eek F, Hofstetter S, Lames M. Injury Patterns among Elite Football Players: A Media-based Analysis over 6 Seasons with Emphasis on Playing Position. Int J Sports Med. 2016;37(11):898-908.

5. Hawkins RD, Fuller CW. A prospective epidemiological study of injuries in four English professional football clubs. Br J Sports Med. 1999;33(3):196-203.

6. Woods C, Hawkins R, Hulse M, Hodson A. The Football Association Medical Research Programme: an audit of injuries in professional football-analysis of preseason injuries. Br J Sports Med. 2002;36(6):436-41.

7. Ekstrand J. Preventing injuries in professional football: thinking bigger and working together. Br J Sports Med. 2016;50(12):709-10.

8. Ekstrand J. Keeping your top players on the pitch: the key to football medicine at a professional level. Br J Sports Med. 2013;47(12):723-4.

9. Hagglund M, Walden M, Magnusson H, Kristenson K, Bengtsson H, Ekstrand J. Injuries affect team performance negatively in professional football: an 11-year follow-up of the UEFA Champions League injury study. Br J Sports Med. 2013;47(12):738-42.

10. Bahr R. Why screening tests to predict injury do not work-and probably never will...: a critical review. Br J Sports Med. 2016;50(13):776-80.

11. McCall A, Carling C, Davison M, Nedelec M, Le Gall F, Berthoin S, et al. Injury risk factors, screening tests and preventative strategies: a systematic review of the evidence that underpins the perceptions and practices of 44 football (soccer) teams from various premier leagues. Br J Sports Med. 2015;49(9):583-9.
12. Hughes T, Sergeant JC, van der Windt DA, Riley R, Callaghan MJ. Periodic Health Examination and Injury Prediction in Professional Football (Soccer): Theoretically, the Prognosis is Good. Sports Med. 2018;48(11):2443-48.

13. Ljungqvist A, Jenoure PJ, Engebretsen AH, Alonso JM, Bahr R, Clough AF, et al. The International Olympic Committee (IOC) Consensus Statement on Periodic Health Evaluation of Elite Athletes, March 2009. Clin J Sport Med. 2009;19(5):347-60.

14. Riley RD, van der Windt DA, Croft P, Moons KG. Prognosis Research in Healthcare: Concepts, Methods and Impact. Oxford: Oxford University Press; 2019.

15. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013;10(2):e1001380.

16. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381.

17. Localio AR. Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making. Ann Intern Med. 2012;157(4):294-6.

18. Bernard A. Clinical prediction models: a fashion or a necessity in medicine? J Thorac Dis. 2017;9(10):3456-7.

19. Hughes T, Sergeant JC, Parkes M, Callaghan MJ. Prognostic factors for specific lower extremity and spinal musculoskeletal injuries identified through medical screening and training load monitoring in professional football (soccer): a systematic review. BMJ Open Sport & Exercise Medicine. 2017;3(1):1-18.

20. Hughes T, Riley R, Sergeant J, Callaghan M. A study protocol for the development and internal validation of a multivariable prognostic model to determine lower extremity muscle injury risk in elite football (soccer) players, with further exploration of prognostic factors. Diagn Progn Res. 2019;3(19).

21. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br Med J. 2015;350:g7594.

22. Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-73.

23. Fuller CW, Ekstrand J, Junge A, Andersen TE, Bahr R, Dvorak J, et al. Consensus statement on injury definitions and data collection procedures in studies of football (soccer) injuries. Br J Sports Med. 2006;40(3):193-201.

24. Mueller-Wohlfahrt HW, Haensel L, Mithoefer K, Ekstrand J, English B, McNally S, et al. Terminology and classification of muscle injuries in sport: the Munich consensus statement. Br J Sports Med. 2013;47(6):342-50.
25. Ekstrand J, Askling C, Magnusson H, Mithoefer K. Return to play after thigh muscle injury in elite football players: implementation and validation of the Munich muscle injury classification. Br J Sports Med. 2013;47(12):769-74.

26. Peduzzi P, Concato J, Kemper E, Holfors TR, Feinstein AR. A Simulation Study of the Number of Events per Variable in Logistic Regression Analysis. J Clin Epidemiol. 1996;49(12):1373-9.

27. Steyerberg EW, Uno H, Ioannidis JPA, van Calster B, Collaborators. Poor performance of clinical prediction models: the harm of commonly applied methods. J Clin Epidemiol. 2018;98:133-43.

28. Hori N, Newton RU, Kawamori N, McGuigan MR, Kraemer WJ, Nosaka K. Reliability of performance measurements derived from ground reaction force data during countermovement jump and the influence of sampling frequency. Journal of Strength & Conditioning Research. 2009;23(3):874-82.

29. Roach S, San Juan JG, Suprak DN, Lyda MA. Concurrent validity of digital inclinometer and universal goniometer assessing passive hip mobility in healthy subjects. Int J Sports Phys Ther. 2013;8(5):680-8.

30. Clapis PA, Davis SM, Davis RO. Reliability of inclinometer and goniometric measurements of hip extension flexibility using the modified Thomas test. Phys Theory Pract. 2008;24(2):135-41.

31. Boyd BS. Measurement properties of a hand-held inclinometer during straight leg raise neurodynamic testing. Physiotherapy. 2012;98(2):174-9.

32. Gabbe BJ, Bennell KL, Wajswelner H, Finch CF. Reliability of common lower extremity musculoskeletal screening tests. Phys Ther Sport. 2004;5(2):90-7.

33. Williams CM, Caserta AJ, Haines TP. The TiltMeter app is a novel and accurate measurement tool for the weight bearing lunge test. J Sci Med Sport. 2013;16(5):392-5.

34. Munteanu SE, Strawhorn AB, Landorf KB, Bird AR, Murley GS. A weightbearing technique for the measurement of ankle joint dorsiflexion with the knee extended is reliable. J Sci Med Sport. 2009;12(1):54-9.

35. Lunt M. nscore Manchester University of Manchester; 2007 [Available from: http://personalpages.manchester.ac.uk/staff/mark.lunt.]

36. Sterne JAC, White IR, Carlin J, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br Med J. 2009;338:b2393.

37. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.
38. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. J Royal Stati Soc. 1999;48(3):313-29.

39. Steyerberg EW, Eijkenmans MJ, Harrell FE, Habbema JDF. Prognostic Modelling with Logistic Regression Analysis: In search of a Sensible Strategy in Small Data Sets. Med Decis Making. 2001;21(1):45-56.

40. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925-31.

41. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and Prognostic Research: Developing a Prognostic Model Br Med J. 2009;338.

42. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the Performance of Prediction Models: a framework for some traditional and novel measures. Epidemiology. 2010;21(1):128-38.

43. Austin PC, Steyerberg EW. Graphical assessment of internal and external calibration of logistic regression models by using loess smoothers. Stat Med. 2014;33(3):517-35.

44. Bewick V, Cheek L, Ball J. Statistics review 14: Logistic regression. Crit Care. 2005;9(1):112-8.

45. Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol. 2018;74(6):796-804.

46. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. Br Med J. 2016;352:i6.

47. Harrell FE. Regression modelling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. New York: Springer; 2015.

48. Bansal A, Heagerty PJ. A comparison of landmark methods and time-dependent ROC methods to evaluate the time-varying performance of prognostic markers for survival outcomes. Diagn Progn Res. 2019;3:14.

49. Meeuwisse W, Tyreman H, Hagel B, Emery C. A Dynamic Model of Etiology in Sport Injury: The Recursive Nature of Risk and Causation. Clinical Journal of Sports Medicine. 2007;17(3):215-9.

50. Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med. 2004;23(16):2567-86.

51. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. Br Med J. 2010;340:c221.
